Chagas Disease — Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease
Citation(s)
Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease